



Vesicular Delivery Systems For Treatment Of Psoriasis

*A Thesis Submitted for Partial Fulfillment of the Requirements for the
Master Degree of Pharmaceutical Sciences
(Pharmaceutics)*

By

Rana Abdel Gawad Moussa

*Bachelor of pharmaceutical sciences, June 2009, Ain Shams University
Pharmacist, National Organization For Drug Control And Research*

Under the supervision of:

Prof. Dr. Gehanne Abd El-Samie Awad

*Professor of Pharmaceutics and Industrial Pharmacy,
Faculty of Pharmacy, Ain Shams University*

Dr. Manal Yassin Hamza

*Associate Professor of Pharmaceutics,
National Organization For Drug Control And Research*

Dr. Maha Nasr Sayed

*Lecturer of Pharmaceutics and Industrial Pharmacy,
Faculty of Pharmacy, Ain Shams University*


Department of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy

Ain Shams University

Cairo

2016



Acknowledgement

First of all thanks to **GOD**, by the grace of whom, this work was successfully achieved.

Deep thanks to **Prof. Dr Gehanne Abd El-Samie Awad**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for her instructive supervision and encouragement throughout the work.

I am greatly thankful to **Dr Manal Yassin Hamza**, Associate Professor of Pharmaceutics, National Organization For Drug Control And Research, for her fruitful supervision.

No words could ever express my deep thanks, and my hearty appreciation to **Dr Maha Nasr Sayed**, Lecturer of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for the great help and effort she devoted for the fulfillment and completion of this thesis.

I would also like to thank **Dr. Noha Moftah**, Faculty of Medicine, Al-Minya University for her help in conduction of the clinical part of the work.

I would like to express my deep thanks to my **Colleagues** in the Department of physical properties at National Organization for Drug Control And Research.

I am profoundly grateful to ***all the members of my family (my beloved father (god rest his soul), my beloved mother, my sisters: Rihome, Rola, Roxane and their families*** who supported and helped me throughout the

work period. Extending gratitude to *my dear husband (Khaled), my daughter (Perry)* for their sincere support and encouragement.

Rana Abdel Gawad Moussa
2016

List of Contents

Item	Page
List of Abbreviations	IV
List of Tables	VI
List of Figures	VIII
Abstract	XII
General Introduction	1
Scope of Work	31
Chapter I: Preparation and Characterization of different tazarotene vesicles	
Introduction	33
Experimental: Materials	35
Experimental: Equipment	36
Methodology	37
HPLC analysis of tazarotene in methanol and phosphate buffer (pH 7.4) containing 10% Tween	37
Preparation of tazarotene vesicles using the thin film hydration method	37
Characterization of tazarotene vesicles prepared according to the factorial design	41
Transmission electron microscopy (TEM)	42

List of Contents

Item	Page
Particle size and zeta potential measurement for ceramide free tazarotene vesicles	43
Differential scanning calorimetry (DSC)	43
<i>Ex vivo</i> skin deposition of tazarotene cerosomes and ceramide free vesicles	44
Assessment of physical stability of tazarotene cerosomal formulae	45
Statistical analysis	45
Results and Discussion	46
HPLC method for determination of tazarotene in methanol and in tweenated phosphate buffer pH 7.4	46
Calibration curve of tazarotene in tweenated buffer pH 7.4 and in methanol	47
Study of different tazarotene vesicles	48
Ceramide free vesicles	56
Particle size, polydispersity index and zeta potential of ceramide free tazarotene vesicles	61
Transmission electron microscopy (TEM)	64
Differential scanning calorimetry (DSC)	71
<i>Ex vivo</i> skin deposition study for ceramide free tazarotene vesicles and cerosomes	73

List of Contents

Item	Page
Determination of the physical stability of selected cerosomal formulations	76
Conclusion	78
Chapter II: Clinical study on selected ceramide containing vesicles on psoriatic patients	
Introduction	80
Experimental	82
Methodology and patients	83
Design of the clinical study	83
Clinical response	84
Results and Discussion	88
Conclusion	94
Summary	95
References	101
Appendix I: Ehical committee, Approval for clinical studies	
Appendix II: Publications	
Arabic Summary	

List of Abbreviations

°C	Degree Celsius
µg	Micrograms
APC	Antigen presenting cells
BSA	Body Surface Area
cm	Centimeters
cm ²	Centimeters square
cp	Centipoises
DSC	Differential Scanning Calorimetry
EE%	Entrapment Efficiency Percent
FDA	Food and Drug Administration
FI	Factor Interaction
g	Grams
HIV	Human immunodeficiency virus
HPLC	High Performance Liquid Chromatography
hrs	Hours
kV	kilo Volts
mg	Milligrams
MHC	Major histocompatibility complexes
min	Minutes
mL	Milliliters
MPEG-dihexPLA	Methoxy-polyethylene glycol- dihexyl substituted polylactide
mV	milli Volts

List of Abbreviations

NLCs	Nanostructured lipid carriers
nm	Nanometers
O/W	Oil in water
PASI	Psoriasis Area and Severity Index
PCS	Photon Correlation Spectroscopy
PDI	Polydispersity index
PEVs	Penetration enhancer vesicles
PUVA	Psoralen and ultraviolet A radiation
rpm	Rotation per minute
S.D	Standard Deviation
SDC	Sodium DeoxyCholate
SL	Soya Lecithin
SLNs	Solid lipid nanoparticles
TEM	Transmission Electron Microscopy
Tween	Tween 80
USP	United States Pharmacopeia
UV	Ultra Violet
W/O	Water in oil

List of Tables

Table number	Table name	Page
1	Composition of preliminary formulated ceramide vesicles without soya lecithin (SL)	38
2a	Composition of tazarotene cerosomes prepared without surfactant	39
2b	Composition of tazarotene cerosomes prepared with surfactant	40
2c	Composition of ceramide free tazarotene vesicles	40
3	Setup of the optimal custom factorially designed experiment	41
4	EE%, viscosity and cumulative amount released after 24 hours of tazarotene cerosomes	49
5	Summary of ANOVA analysis of the model derived from the factorial study determining the significance of the variables on EE% of cerosomes	50
6	Summary of ANOVA analysis of the model derived from the factorial study determining the significance of the variables on viscosity of cerosomes	54
7	EE%, viscosity and cumulative amount released after 24 hours of tazarotene (ceramide free) vesicles	56
8	Particle size, polydispersity and zeta potential of tazarotene control vesicles	62
9	Percentages of tazarotene retained in rat skin at different time intervals up to 72 hours for cerosomal formulae and for marketed product	73
10	Percentages of tazarotene retained in rat skin at different time intervals up to 72 hours for ceramide free formulae	74
11	Change in tazarotene EE% values after one year storage at refrigeration temperature	76

List of Tables

Table number	Table name	Page
12	Demographic data of group 1 patients receiving formula 1 on lesion (A1)/Acnitaz® gel on lesion (B)	86
13	Demographic data of group 2 patients receiving formula 6 on lesion (A2)/Acnitaz® gel on lesion (B)	87
14	PASI scores for group 1 patients before and after treatment with formula 1 on lesion (A1) and Acnitaz® gel on lesion (B)	88
15	PASI scores for group 2 patients before and after treatment with formula 6 on lesion (A2) and Acnitaz® gel on lesion (B)	89

List of Figures

Figure number	Figure name	Page
I	Stages involved in psoriasis pathogenesis	3
II	Various colloidal carriers used for drug delivery	7
III	A representation of the structure of a liposome	9
IV	Structure of a nonionic surfactant vesicle (niosome)	11
V	A representation of transfersomal vesicle	13
VI	Schematic diagram describing interaction of a transfersome with skin	13
VII	Ultradeformable transfersomes compressing through minute pores in the stratum corneum	13
VIII	A representation of an ethosomal vesicle	14
IX	Schematic model for skin delivery using an ethosomal system	15
X	Proposed model for ethosomal interaction with the skin lipids	15
XI	Models of drug incorporation into SLN	17
XII	A comparison in structure between SLNs and NLCs	20
XIII	Schematic representation of a liposphere particle	21
XIV	Diagram of polymeric micelles	24
XV	Structure of a dendrimer molecule	25
XVI	Difference between matrix and capsular system	25
XVII	Different nanocapsular structures	27

List of Figures

Figure number	Figure name	Page
XVIII	Structure of tazarotene	28
XIX	Structure of ceramide VI	30
1	HPLC chromatogram of tazarotene in tweenated buffer PH 7.4	46
2	HPLC chromatogram of tazarotene in methanol	46
3	Calibration curve of tazarotene in methanol at 345 nm	47
4	Calibration curve of tazarotene in tweenated buffer pH 7.4 at 345 nm	48
5	Effect of ceramide: surfactant ratio, type of surfactant and presence of ethanol on the EE% of tazarotene cerosomes	51
6	Effect of ceramide: surfactant ratio, type of surfactant and presence of ethanol on the viscosity of tazarotene cerosomes	53
7	EE% of ceramide free tazarotene vesicles	57
8	Effect of type of surfactant on EE% of ceramide free tazarotene vesicles	57
9	Effect of ethanol addition on EE% of ceramide free tazarotene vesicles	58
10	Effect of ceramide presence on EE% of tazarotene	58
11	Viscosity of ceramide free tazarotene vesicles	59
12	Effect of ceramide presence on viscosity of tazarotene containing formulations	60
13	Particle size of ceramide free tazarotene vesicles	63

List of Figures

Figure number	Figure name	Page
14	Effect of ethanol addition on the particle size of ceramide free tazarotene vesicles	63
15	Effect of type of surfactant on particle size of ceramide free tazarotene vesicles	63
16	Electron micrographs of liposomes (formula 20) at a magnification of a) 20000x b) 40000x	65
17	Electron micrographs of transfersomes with Tween (formula 16) at a magnification of A) 100000x B) 80000x	65
18	Electron micrographs of transfersomes with SDC (formula 18) at a magnification of A) 15000x and B) 20000x	66
19	Electron micrograph of transthesomes (formula 19) at a magnification of 100000x	66
20	Electron micrograph of transthesomes with Tween (formula 17) at a magnification of 80000x	67
21	Different electron micrographs (A-D) of cerosomal (formula 1) at a magnification of 80000x	68
22	Electron micrographs of cerosomal (formula 6) at a magnification of A)5000x B)15000x	69
23	Electron micrograph of cerosomal (formula 7) at magnification of A)20000x B)5000x C)25000x.	69
24	Electron micrographs of cerosomal (formula 10) at a magnification of A) 40000x B) 80000x C) 50000x D) 30000x	70
25	Electron micrographs of cerosomal (formula 9) at a magnification of 25000x	71

List of Figures

Figure number	Figure name	Page
26	DSC thermograms of tazarotene, ceramide, plain and drug loaded cerosomes and transethosomes	72
27	Percentage of tazarotene retained in rat skin within 3 consecutive days for selected cerosomal formulations and control vesicles	74
28	Effect of ceramide addition on ex vivo retention of tazarotene in rat skin	75
29	Change in tazarotene EE% values after one year storage at refrigeration temperature	77
30	Male patient presenting with plaque psoriasis over right (a) and left (c) forearms.	91
31	Male patient presenting with plaque psoriasis over right (a) and left (b) knees	92